Jupiter Life Line Hospitals Ltd

- For the three new hospitals planned (Dombivli, Pune 2 in Bibvewadi, Mira Road), no additional debt is currently planned. - The company intends to fund these projects through internal accruals and existing cash reserves. - The current cash on books is Rs. 250+ crores and nine-month EBITDA is Rs. 218 crores. - Since the hospital expansions are greenfield projects, CAPEX expenditure is staggered, allowing cash deployment as it is generated. - If future opportunities arise beyond the current three hospitals, the board will evaluate the need to raise debt, equity, or a mix of both at that time. - Financing decisions will be made based on the nature and timing of those opportunities. In summary, no immediate plans for fresh fundraising through debt or equity; current projects will be funded via internal resources, with future funding evaluated as needed.

- Current CAPEX for FY25 (9 months) excluding recent land acquisition is around Rs. 100 crores, mainly for Dombivli and Indore projects. - Total planned CAPEX for three new hospitals (Dombivli, Pune 2 at Bibvewadi, Mira Road) is approximately Rs. 1,400 crores. - Land acquisition in Mira Road for around Rs. 75 crores, fully funded through internal accruals and equity reserves. - Mira Road hospital planned as a 300-bed full-service multi-specialty hospital with an estimated total CAPEX of Rs. 400 crores (including land). - Dombivli hospital expected operational by Q1 FY27 with staggered investment. - The company intends to fund these projects largely through existing cash reserves (Rs. 250+ crores), internal accruals, and cash flow without additional debt for now. - Possibility of future funding through debt or equity will be evaluated if new projects arise beyond these three hospitals.

- Revenue for Q3 FY25 stood at Rs. 322 crores, a 17.7% YoY increase; 9-month revenue was Rs. 934.8 crores, up 19.5% YoY. - Volume increased from 651,500 to 727,500 in 9 months. - Occupancy improved to 66.7% from 63.2% YoY. - ARPOB (Average Revenue Per Occupied Bed) increased to Rs. 59,100 from Rs. 53,600 YoY. - Expansion via three new hospitals (Dombivli 500 beds by Q1 FY27, Pune 500 beds by 2028, Mira Road 300 beds by 2029) aims to increase bed capacity to ~2,500. - Industry norm suggests new hospitals will be EBITDA negative in year 1, breakeven in year 2, and positive in year 3. - Demand in catchment areas, such as Mira Bhayandar with 2-3 million underserved residents, can drive volume growth. - Margins expected to improve with occupancy growth, price hikes, and case-mix optimization, particularly in Pune and Indore.

- Jupiter Life Line Hospitals anticipates initial EBITDA losses for new hospitals in the first year, with breakeven expected by the second year and profitability by the third year. - Margin expansion levers include inflation-linked price hikes (Thane), occupancy growth (Pune), and case mix optimization (Indore) expected to continue for 1-1.5 years. - Occupancy rates are poised to improve, with current occupancy around 65-66%, and planned bed additions to manage demand. - ARPOB is increasing (Rs 61,750 in Q3 FY25 vs. Rs 59,100 in 9 months FY25), supporting revenue growth. - The company projects growing internal accruals without immediate need for additional debt, supporting capital expenditure for new hospitals. - With three new hospitals planned by FY27-FY29, revenue and profits are expected to scale up steadily as these facilities stabilize and grow.

- Jupiter Life Line Hospitals has a pipeline of three new hospitals in addition to the existing three operational ones. - New hospitals planned: - Dombivli: 500 beds, expected operational by Q1 FY27. - Pune 2 (Bibvewadi): 500 beds, expected operational in calendar year 2028. - Mira Road: 300 beds, expected operational in calendar year 2029. - Total bed capacity after new hospitals will be approximately 2,500 beds. - Estimated CAPEX for these three hospitals is around Rs. 1,400 crores. - Recent land acquisition in Mira Road was for Rs. 75 crores, part of the Rs. 400 crore estimated CAPEX for that hospital. - Funding for the CAPEX will come from current cash reserves, internal accruals, and no immediate additional debt is planned. - No formal EBITDA loss guidance, but first-year EBITDA expected negative and breakeven by the second year for new hospitals.